A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary) ; RLY-2608 (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Head and neck cancer; HER2 negative breast cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms ReDiscover
- Sponsors Relay Therapeutics
- 09 Sep 2024 According to a Relay Therapeutics media release, company plans to initiate RLY-2608 monotherapy solid tumor dose expansion cohort(s) by the end of 2024
- 06 Sep 2024 According to a Relay Therapeutics media release, company plans to host a conference call and webcast to report data from this study.
- 06 Aug 2024 According to a Relay Therapeutics media release, data update is expected in the fourth quarter of 2024.